For the standardized reporting of disease extent in histologically confirmed PCa, the PROMISE framework (Prostate Cancer Molecular Imaging Standardized Evaluation) was introduced in 2018 and updated in 2023, integrating findings from whole-body PSMA-PET imaging. This evidence concerns the gene FOLH1 and Familial prostate cancer.